Table 3.
AMR profiles of Aeromonas spp. isolated in 2013 and 2016
| Antimicrobials | No. of resistant isolates (%) | Chi-square index (χ2) | |
|---|---|---|---|
| 2013 | 2016 | ||
| Cloxacillin | 31 (100) | 64 (100) | / |
| Spiramycin | 31 (100) | 64 (100) | / |
| Tilmicosin | 31 (100) | 64 (100) | / |
| Ampicillin | 30 (96.8) | 64 (100) | 0.14 |
| Tylosin | 31 (100) | 63 (98.4) | 0 |
| Penicillin | 31 (100) | 62 (96.9) | 0.05 |
| Amoxicillin | 29 (93.5) | 63 (98.4) | 0.43 |
| Sulfadiazine | 31 (100) | 61 (95.3) | 0.36 |
| Tiamulin | 27 (87.1) | 54 (84.4) | 0 |
| Neomycin** | 12 (38.7) | 45 (70.3) | 7.42 |
| Erythromycin** | 25 (80.6) | 30 (46.9) | 8.43 |
| Cephaloridine* | 23 (74.2) | 28 (43.8) | 6.61 |
| AMC* | 8 (25.8) | 35 (54.7) | 5.91 |
| Apramycin** | 6 (19.4) | 33 (51.6) | 7.67 |
| Tetracycline* | 10 (32.3) | 8 (12.5) | 4.1 |
| SXT | 8 (25.8) | 8 (12.5) | 1.78 |
| Nalidixic acid | 5 (16.1) | 10 (15.6) | 0 |
| Thiamphenicol** | 9 (29.0) | 4 (6.3) | 7.35 |
| Kanamycin | 2 (6.5) | 9 (14.1) | 0.56 |
| Danofloxacin | 1 (3.2) | 8 (12.5) | 1.15 |
| Enrofloxacin | 4 (12.9) | 4 (6.3) | 0.49 |
| Flumequine | 1 (3.2) | 6 (9.4) | 0.43 |
| Aminosidine | 1 (3.2) | 5 (7.8) | 0.17 |
| Colistin | 1 (3.2) | 5 (7.8) | 0.17 |
| Ceftiofur | 2 (6.5) | 4 (6.3) | 0 |
| Doxycycline | 2 (6.5) | 3 (4.7) | 0 |
| Florfenicol | 0 | 3 (4.7) | 0.36 |
| Gentamicin | 1 (3.2) | 2 (3.1) | 0 |
| Marbocyl | 1 (3.2) | 2 (3.1) | 0 |
| Cefquinome | 0 | 0 | / |
Significant differences between Aeromonas spp. isolated in 2013 and 2016 were indicated by: * P < 0.05; ** P < 0.01; *** P < 0.001